Dasatinib Quercetin Delay Spinal Degeneration in Mice

ByHealthspan Editorial
🟢
Peer-Reviewed Research

Dasatinib and Quercetin Delay Spinal Degeneration in Susceptible Mice

A senolytic drug combination of dasatinib and quercetin reduces spine damage in mice prone to early aging of spinal discs. Work led by E.J. Novais and M.V. Risbud at Thomas Jefferson University found the treatment lowered disc degeneration grades, improved cell survival, and reduced markers of cellular senescence. These results, published in Bone Research, reinforce that clearing aged, dysfunctional cells can protect a specific tissue—in this case, the intervertebral disc.

What Are Senolytics and How Do They Work?

Senolytics are a class of molecules designed to selectively eliminate senescent cells. These are cells that have entered a state of permanent growth arrest in response to stress but remain metabolically active. Instead of dying, they secrete a harmful mix of inflammatory signals, growth factors, and proteases known as the senescence-associated secretory phenotype (SASP). This SASP creates a toxic local environment, damaging nearby healthy cells and driving tissue dysfunction.

The Senolytic Strategy: Targeting Survival Pathways

Unlike traditional anti-inflammatory drugs, senolytics aim for the root cause by removing the source of the inflammation. Senescent cells depend on specific pro-survival pathways to avoid their own programmed cell death. Dasatinib and quercetin, often abbreviated as DQ, target different components of these networks. Dasatinib is a tyrosine kinase inhibitor that affects pathways like Src and Bcl-xL. Quercetin, a flavonoid found in plants, influences other survival dependencies, including those involving PI3K and Bcl-2. Used together, they have a broader senolytic effect, increasing the elimination of these harmful cells.

New Evidence from the Spine and Jawbone

Two studies from 2026 provide direct experimental evidence for the tissue-protective effects of DQ in aging mammals.

Delaying Disc Degeneration in a Genetic Model

The SM/J mouse strain is genetically predisposed to early, severe intervertebral disc degeneration, mirroring aspects of human back disease. The Jefferson University team tested two senotherapeutics against this background: navitoclax and the DQ cocktail. While navitoclax failed to improve the condition, DQ treatment produced measurable benefits. Treated mice showed less severe structural degeneration, a drop in senescence markers (p19ARF, p21), and a dampened SASP. The nucleus pulposus tissue at the disc’s core retained a healthier phenotype and showed less fibrosis.

Transcriptomic analysis pointed to two key processes affected by DQ: cell cycle regulation and JNK signaling. Follow-up experiments on human disc cells suggested inhibiting the JUN pathway, part of the JNK cascade, mimicked DQ’s benefits by reducing senescence and SASP factors. “This study reinforces the efficacy of senolytic treatment in ameliorating local senescence and intervertebral disc fibrosis,” the authors concluded. It connects a cellular process to a structural outcome in a clinically relevant model.

Preventing Age-Related Bone Loss in the Jaw

Separate research from São Paulo State University examined alveolar bone, the structure that anchors teeth. Led by A.L. Anbinder, the study found that aged mice treated with DQ experienced significantly less alveolar bone loss compared to untreated peers. The treatment reduced the number of senescent cells and lowered local levels of inflammatory cytokines like IL-6 and TNF-α, hallmarks of the SASP. This work, accepted in the Journal of Periodontology, directly links the removal of senescent cells to the preservation of oral bone structure during aging.

The study’s limitation, like most preclinical work, is its use of a mouse model. Human periodontal disease involves complex oral biofilms, but the findings establish a clear mechanistic link between cellular senescence and bone resorption in aging tissue.

How DQ Targets Senescence Across Tissues

The apparent success of DQ in two distinct musculoskeletal tissues—spinal discs and jawbone—suggests a common mechanism of action: reducing the senescent cell burden and its inflammatory fallout.

The JNK Signaling Pathway as a Common Target

A key finding from the spinal disc study is the involvement of the JNK pathway. Transcriptomic data from DQ-treated mice showed altered JNK signaling in disc tissue. In human disc cells, direct pharmacological inhibition of the downstream JUN pathway reduced senescence markers and SASP factors, replicating the DQ effect. This identifies a specific molecular pathway that DQ may modulate to achieve its benefits, offering a target for future, more precise senolytic development.

Contrasting Results with Navitoclax

The failure of navitoclax in the SM/J mouse model is an important detail. Navitoclax is a potent senolytic that inhibits Bcl-2 family proteins. Its lack of efficacy here indicates that not all senolytic agents work in every tissue or context. The success of DQ likely hinges on its ability to target the specific survival networks active in disc cells, highlighting that senescent cell populations are heterogeneous. An effective senolytic strategy must match the target cells’ dependencies.

Practical Applications and Current Research Status

Dasatinib is an approved chemotherapy drug, and quercetin is a dietary supplement. Their combined use as a senolytic is experimental.

Human Clinical Trials

Early-phase clinical trials are exploring DQ in humans for conditions like idiopathic pulmonary fibrosis and chronic kidney disease. These studies primarily assess safety and biomarkers. No large-scale, long-term trials have yet proven DQ extends healthspan or prevents age-related diseases in people. The jump from mouse models, which have shorter lifespans and controlled genetics, to the complexity of human aging is significant.

For more on related experimental approaches, see our guide on partial reprogramming for epigenetic rejuvenation.

Safety and Accessibility Considerations

Dasatinib has known side effects, including myelosuppression and fluid retention, from its use in oncology. Its off-label use for senescence carries these risks without established dosing guidelines for healthy aging. Quercetin is generally considered safe at supplement doses, but its bioavailability is low, and high-quality human data on its long-term senolytic efficacy is absent. Self-administering a DQ protocol outside of clinical supervision is not supported by current evidence and carries potential health risks.

Actionable Takeaways for Healthspan

While DQ is not a ready-made solution, the science of senescence points to actionable strategies.

Lifestyle Interventions with Senomorphic Effects

Certain behaviors can suppress the SASP or may help prevent the accumulation of senescent cells, acting as “senomorphics.” These include:

  • Regular Exercise: Physical activity is associated with reduced markers of senescence and inflammation. For details, read our article on exercise and mitochondrial health in aging muscle.
  • Dietary Modifications: Caloric restriction and intermittent fasting regimens can reduce senescent cell burden in animal models. Our guide on intermittent fasting covers the evidence.
  • Specific Nutrients: Compounds like fisetin and piperlongumine show senolytic activity in preclinical studies. Quercetin itself, as a dietary component from foods like capers, apples, and onions, may contribute to a senescence-suppressing diet.

The Role of Other Pharmacological Approaches

DQ is one of several investigational senotherapeutics. Others include the Bcl-2 inhibitor navitoclax and the natural compound fisetin. Metformin, a diabetes drug, has senomorphic properties and is being tested for its effects on aging in the large TAME trial. For a comprehensive review, see our evidence-based guide to metformin.

Key Takeaways

Similar Posts